角膜胶原交联(CXL)是一种用于治疗圆锥角膜的新技术，其主要特点是利用370nm波长的紫外线A照射核黄素产生的光敏反应来诱导角膜胶原纤维间的交联，以此提高角膜硬度，增强角膜生物力学稳定性。该方法目前已被应用于多种角膜疾病的治疗，并取得了较理想的临床疗效。但最近也有文献报道经典交联方法术前去角膜上皮所引起的一些术后不良反应和并发症。针对去角膜上皮引起的术后不良反应和并发症有学者提出了跨角膜上皮核黄素-紫外线胶原交联法。本文主要对角膜胶原交联的基本原理、操作方法、去角膜上皮的影响及近年来跨上皮交联方法的研究与应用情况进行综述。

Corneal collagen cross-linking(CXL) is a new treatment for keratoconus. Based on the topical administration of riboflavin and irradiation with ultraviolet A (UVA) light of 370nm, this procedure can lead to photosensitive reaction and thus to induce cross-linking between and within collagen fibrils in order to increase rigidity and biomechanical stability of the cornea. This new approach has been also shown to be an effective treatment for some kinds of other corneal diseases. However, recently, adverse effects and complications related to epithelial removal have been reported. For this reason, researchers proposed the transepithelial corneal collagen cross-linking. The purpose of this paper is to review the basic principle, procedure, effect of epithelial removal and the laboratory and clinical researches about transepithelial corneal collagen cross-linking with Riboflavin/UVA.